cri-one
Contents
100%
Your journey

OTC Vitamins for Children and Adults

Inventory item: 8447 | SKU: 2028 | Line: Blueprints

Page: https://cri-one.com/02-otc-vitamins.html

Owner and author: Christopher Gabriel Brown (CRI-ONE)

Record date: 8 October 2026

Flag: APPROVED PUBLIC WORDING item (medical/regulatory wording uses descriptions-public)

1. The Record in Brief

OTC Vitamins for Children and Adults is a complete line of nine over-the-counter vitamin and supplement formulations, four KidVital children's products and five VitalCore adult products, each designed from the Alchemy probability data and element tables across five life stages (D:/special/02-otc-vitamins/README.md). The earliest dated disclosure of record is deposition 328, a children-specific dose measurement formula marked copyright 2017 in the master IP register. U.S. Application No. 19/693,405, filed 30 May 2026 and pending, names this product as Project 2 and claims the cohort-banded formulation in claim 15. The line was first publicly listed on the old cri-one.com store on 9 March 2026, and its card Buy button went live on the new item page at 05:06 UTC on 8 October 2026. The package carries the notice "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved."

2. Proprietary - What Is Owned and How It Is Held

The package is the folder D:/special/02-otc-vitamins/: 35 files in seven sub-folders and the root (_TOC.md, generated 2026-10-06). Its file families are:

  • Formulation data: 10 JSON files, nine complete formulations (compound, amount and % Daily Value per ingredient) and master_ingredient_database.json cataloging 46 unique compounds.
  • Alchemy analysis: 3 files, the life-stage element differences, the nutrient probability model and the age-cohort absorption-rate tables.
  • Regulatory: 4 files, FDA OTC/DSHEA compliance, GMP manufacturing specification, label requirements and allergen matrix.
  • Packaging: 2 specifications, one per brand line.
  • Sales and handoff: 4 sales files, the handoff checklist and the handoff summary.
  • Pictures: the hero drawing (SVG) and the product image (PNG).
  • Root records: README, internal PLAYBOOK, LICENSE, MANIFEST.json, CHANGELOG, CITATION.cff, web description and contact file.

The delivery file of record is 02-otc-vitamins__2026-09-04.zip (1,371,718 bytes), the file the old store's download linked (D:/special/crione-static/delivery-v2/product_deliverables.csv).

Ownership is sole. The LICENSE states that the Work is "the exclusive property of Christopher Gabriel Brown", and CITATION.cff names him as sole author. No assignment appears in the record. A buyer receives use, not ownership: the LICENSE reads "NO LICENSE IS GRANTED." beyond the owner's express written permission, and the purchase term at https://cri-one.com/terms, accepted at checkout, reads "When you buy, you buy the use of that blueprint only."

Trade-secret protection under 18 U.S.C. 1839(3) covers information that derives value from not being generally known and is kept under reasonable secrecy measures. The measures of record: the full package is delivered only to paying buyers by private download link valid 7 days, after the owner approves the order; the full text of the mutual NDA published at https://cri-one.com/nda/ is carried in every delivery e-mail (D:/special/crione-static/delivery-v2/deliver.py); the LICENSE is headed "PROPRIETARY AND CONFIDENTIAL"; the PLAYBOOK is marked internal; the public item page carries only the description.

3. First Art - The Earliest Dated Disclosure

DateRecordWhat it disclosesSource
2017 (mark in text)Deposition 328, register line 1011Children-specific dose measurement formula1 light trigger.txt; entries-clean.csv
2017 (mark in text)Deposition 486, register line 1186Computational predictive alchemy studies1 light trigger.txt; entries-clean.csv
2018 (mark in text)Deposition 1399, register line 445Vitamins engineered to a deficiency1 light trigger.txt; origin story 1399
2026-03-09Store listing, SKU OTC-VITAMINS-02The OTC Vitamins for Children and Adults lineexport_catalog_product_20260408_165843.csv
2026-05-02Package LICENSE and MANIFEST generated27-file package with ten formulation data files (nine formulations and the master ingredient database)LICENSE; MANIFEST.json
2026-05-30U.S. Application No. 19/693,405Project 2, embodiment [0022], claim 15N417.PYMT (3).pdf; NONPROVISIONAL-CGB-Framework.docx

The deposition anchors come from D:/Rebuttals/_registers/DEPOSITIONS_A.json (id 8447), confirmed against the master IP register D:/special/82-alchemy-calc-two/1 light trigger.txt. All three are anchored in the 2017 catalog (entries-clean.csv), the buyinvent.com catalog dump of 1,739 entries:

  • Deposition 328 (ancestor): "children specific dose measurement solvent formula", marked "copyright © 2017 chris g brown"; the principle behind a separate children's line.
  • Deposition 1399 (ancestor; origin story on file): "g-m-vitamins are genetically modified vitamins that encourage growth to patients with severe deficiencies in a certain vitamin or cell of the body", marked "copyright (c) 2018 chris gabriel brown".
  • Deposition 486 (ancestor; origin story on file): "computational predictive plasma sorting lapidary alchemy studies", marked copyright 2017; the origin of the Alchemy methodology.

Under 35 U.S.C. 102(a)(1), a printed publication, public use, sale or other public availability before a filing date is prior art against that filing. The owner's dated public disclosures of this line, from the store listing of 9 March 2026 to the item page of 8 October 2026, are prior art against every later filer, to the full extent of what each discloses. A challenger must produce a dated record earlier than 9 March 2026 disclosing the same combination (nine age-banded formulations whose compounds and doses are set from a deficiency-probability model and age-cohort absorption tables), and a record earlier than the 2017 mark of deposition 328 disclosing its children-specific dose formula. None is of record.

Prior Art Considered and Distinguished

The package holds no product-specific search file. The owner's provenance record (crione-provenance.json, key 2028) attaches six portfolio-level references to this item, and the prior-art register maps the same six to id 8447. These were considered:

ReferenceTitle as recordedDistinction
US 4,775,876Photon recycling light emitting diodeLED photon recycling; owner note: foundational photon-recycle art
US 6,175,719 B1Multi-Spot-Beam SatelliteSatellite payload; owner note: expired
US 7,418,236 B2Extraterrestrial Communications SystemsSatellite-terrestrial communication; owner note: expired
US 11,258,379 B2Quantum Noise Power DevicesQuantum energy harvesting; owner watch list
US 2010/0183919 A1Quantum dot ultracapacitor and electron batteryQuantum-dot energy storage
US 2012/0305059 A1Photon recycling in an optoelectronic deviceOptoelectronic photon recycling

Each recorded subject is energy, optics or satellite communication. The product's documented structure is a nutrient formulation line: nine cohort-banded formulations, a 46-compound ingredient database and a nutrient probability model.

4. First to File - The USPTO Record

U.S. ApplicationFiledStatus of recordWhat it covers for this productSource
19/693,4052026-05-30Pending; Filing Receipt mailed 2026-06-25 (20 claims, 3 independent)Table 2 Project 2 "OTC Vitamins (KidVital / VitalCore)"; embodiment [0022]; claim 15N417.PYMT (3).pdf; 20160101_000000(35).PDF; USPTO_REGISTER.json

Applications with an effective filing date on or after 16 March 2013 are examined under first-inventor-to-file, and every application is dated by its own effective filing date. The USPTO Electronic Payment Receipt shows U.S. Application No. 19/693,405 (confirmation [redacted], Patent Center 76837851) received on 30 May 2026 at 04:30:53 PM ET. The Filing Receipt lists no domestic benefit claim; the application stands on its own effective filing date of 30 May 2026. Its as-filed specification lists this product in Table 2 as Project 2, "OTC Vitamins (KidVital / VitalCore)", on the Dimensional Fold kernel, and paragraph [0022] sets out the worked cohort-formulation embodiment: five age cohorts, five formulations, each optimized to its cohort's absorption profile. Claim 15, exact as filed (D:/manager/work/2 current_work_catalog.txt), recites "a cohort-banded formulation" with "a distinct formulation for each cohort of a plurality of cohorts that is closer to a per-cohort optimum than a single universal formulation." That is this product's structure: distinct formulations for its children's (ages 4-12), adult (18+ and 30+) and 50+ cohorts (formulations/). Under 35 U.S.C. 292, "patent pending" marking is correct while an application is pending; this one is pending on 8 October 2026.

Patent pending - U.S. Application No. 19/693,405.

5. First to Market - The Dated Public Offering

DateEventWhereSource
2011-01-28First Internet Archive capture of cri-one.comweb.archive.orgwayback_evidence.json
2026-03-09Listing "OTC Vitamins for Children and Adults" (SKU OTC-VITAMINS-02) createdOld cri-one.com storeexport_catalog_product_20260408_165843.csv
2026-04-04"Product Deposition: OTC Vitamins for Children and Adults" (SKU PDEPO-02) createdOld cri-one.com storeexport_catalog_product_20260408_165843.csv
2026-04-19Provenance ledger records the listing as first postedcri-one.com/store/first-to-market-LEDGER.csv
2026-08-31Blueprint record 02-otc-vitamins (SKU 2028) createdOld store, Enterprise blueprintsexport_catalog_product_20260831_201548.csv
2026-09-01Record re-created; kept in the 2026-09-07 exportOld storeexport_catalog_product_20260907_110415.csv
2026-09-04Delivery file of record datedDelivery copiesproduct_deliverables.csv
2026-10-08Item page published on the new static sitehttps://cri-one.com/02-otc-vitamins.htmlitem-8447/index.html
2026-10-08 05:06 UTCStripe card Payment Link (created 04:55:52Z) live as the Buy buttonItem pagepayment_links_ledger.live.json

Register of record: D:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json (products "8447"). The first new-site email campaign to US company prospects started on 8 October 2026 at 03:55 UTC (FIRST_TO_MARKET_REGISTER.json, site events; campaign definition D:/special/_mailer/campaigns/new-site-2026-10/campaign.json).

6. Copyright

The package line is "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (LICENSE). The product card carries "© 2026 Christopher Gabriel Brown. All rights reserved." and the item page carries "© 2026 Christopher Gabriel Brown (CRI-ONE), cri-one.com."

The works covered are the text (README, analysis, regulatory, packaging, sales and handoff documents), the data compilations (nine formulation files and the 46-compound master ingredient database, in their selection, coordination and arrangement), the drawing and picture (hero SVG, product image) and the web descriptions (HTML). Copyright arose automatically on fixation (17 U.S.C. 102(a)); the LICENSE and MANIFEST date the package to 2 May 2026. Copyright protects this expression, not the ideas or methods (17 U.S.C. 102(b)); method and structure are held by U.S. Application No. 19/693,405 and by confidentiality.

The owner's written corpus is anchored at the Copyright Office by 20 registrations verified in D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json, effective from 1 October 2010 (TX 7-491-093, invent cloud) to 15 March 2026 (TX 9-504-677, estimated), among them TX 8-396-625 (abstract, 9 May 2017) and TX 8-657-127 (buy text, 4 October 2018). Registration is the gateway to suit for U.S. works (17 U.S.C. 411(a)); a certificate made within five years of first publication is prima facie evidence of validity (17 U.S.C. 410(c)).

Human authorship: protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core here is human-authored: the numbered depositions written by Christopher Gabriel Brown, and his selection, coordination and arrangement of the package.

Notice practice: the owner marks his work in his own name, from the catalog dump (1,270 catalog marks dated 2017 and 287 dated 2018, per the copyright register) to this package's LICENSE. The notice defeats an innocent-infringer defense (17 U.S.C. 401(d)).

7. Firm Rebuttals

Challenge 1 - "Multivitamins are old. Nothing here is original."

Rebuttal. The record claims the combination: nine formulations banded to age cohorts (children 4-12; adults 18+, 30+ and 50+), with compounds, chelation forms and doses set from a five-life-stage deficiency-probability model and age-cohort absorption tables (alchemy-analysis/, formulations/). Deposition 328 disclosed a children-specific dose formula under a 2017 mark; deposition 1399 disclosed vitamins engineered to a deficiency under a 2018 mark. A challenger must produce a dated record earlier than 9 March 2026 disclosing the same combination. None is of record; the six references considered (Section 3) lie in other fields.

Challenge 2 - "Someone else filed first."

Rebuttal. Every application is dated by its own effective filing date. U.S. Application No. 19/693,405 carries 30 May 2026 on the USPTO's own receipt, and the owner's public disclosures from 9 March 2026 are prior art against any later filer under 35 U.S.C. 102(a)(1), to the full extent of what they disclose. A challenger must produce an application with an earlier effective filing date claiming the cohort-banded formulation of claim 15. None is of record.

Challenge 3 - "No patent has issued, so there is nothing to enforce."

Rebuttal. The owner holds a pending application, correctly marked "patent pending" under 35 U.S.C. 292, plus copyright in the package expression, trade-secret measures over the package as delivered, and a contractual purchase term accepted at checkout. Each right stands on its own record.

Challenge 4 - "The formulas are on a public web page, so they are free to use."

Rebuttal. Publication is not a license. The public page carries the description; the full package goes only to paying buyers by private download link, under the term "When you buy, you buy the use of that blueprint only." and with the full text of the published mutual NDA in the delivery e-mail. The description's text is the owner's copyrighted expression, and the LICENSE reads "NO LICENSE IS GRANTED." The publication also works for the owner: it is dated prior art against any later filer on the same subject matter.

Challenge 5 - "AI made it, so there is no copyright."

Rebuttal. Protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office guidance, March 2023). Depositions 328, 486 and 1399, the written records behind this line, are his text, and the selection of nine products, five life stages and 46 compounds and their arrangement into the package are his. CITATION.cff names him as sole author.

Challenge 6 - "The dates can be faked."

Rebuttal. The dates rest on third-party records. The USPTO receipt for 19/693,405 carries the USPTO's own receipt time, confirmation number [redacted] and Patent Center number 76837851. The Internet Archive first captured cri-one.com on 2011-01-28 and buyinvent.com on 2014-03-05 (wayback_evidence.json). Stripe created the card Payment Link at 2026-10-08T04:55:52Z. Every file cited is fingerprinted by SHA-256 in Section 8 and D:/Rebuttals/_evidence/8447.sha256; the master IP register hash matches the deposition register's recorded value, and the First-to-Market evidence file recomputes on 8 October 2026 to its 9 June 2026 fingerprint.

Challenge 7 - "The application is a computing framework; it does not cover vitamins."

Rebuttal. The as-filed specification of 19/693,405 names "OTC Vitamins (KidVital / VitalCore)" as Project 2 in Table 2, sets out the cohort-formulation embodiment in paragraph [0022], and claim 15 recites "a cohort-banded formulation" with "a distinct formulation for each cohort" (NONPROVISIONAL-CGB-Framework.docx; 2 current_work_catalog.txt). The product is a cohort-banded formulation line with a distinct formulation set for each age cohort; it falls squarely within claim 15.

Challenge 8 - "The deficiency probabilities and absorption coefficients are invented numbers."

Rebuttal. The figures are defined in the package's own model. For each nutrient N at life stage S, the model sets P(deficiency | S) from the Alchemy element tables, an age-adjusted Absorption(N, S), and a Dose(N, S) targeting P(adequate) > 0.95 (nutrient_probability_model.md). Its stated data source: values "derived from the Alchemy probability data set and element tables", calibrated against published RDA/AI values. The figures stand as written, for example vitamin D3 at senior stage: P(deficiency) 0.72, absorption coefficient 0.52, dose 4,000 IU.

Challenge 9 - "This is a health product making medical claims."

Rebuttal. This item is a research and discovery IP record and makes no treatment claim. Its public wording is the approved text at D:/special/_inventory/descriptions-public/8447.md. The package's own regulatory file classifies the line as dietary supplements under DSHEA and states "No disease claims; structure/function claims only (21 CFR 101.93)" (regulatory/fda_otc_compliance.md).

Challenge 10 - "It is just an idea."

Rebuttal. The package is concrete: nine formulation data files with compound, amount and % Daily Value per ingredient, a 46-compound master ingredient database, three analysis files carrying the probability model and absorption tables, four regulatory files, two packaging specifications, a handoff checklist, a drawing and a product image, delivered as 02-otc-vitamins__2026-09-04.zip (SHA-256 beginning cacaeebfc96c2cc8).

8. Evidence Index

#FileSHA-256 (first 16 hex)What it proves
1D:/special/02-otc-vitamins/LICENSEab97e3bdd03c4d77Notice, sole ownership, no license granted
2D:/special/02-otc-vitamins/MANIFEST.json17dc905bd3f3b2e1Package generated 2026-05-02
3D:/special/02-otc-vitamins/README.md857e670c61ac160dProduct definition, nine formulations
4D:/special/02-otc-vitamins/formulations/master_ingredient_database.jsonf09b09ee228b320146-compound data compilation
5D:/special/02-otc-vitamins/alchemy-analysis/nutrient_probability_model.mdc36c092730bb4e29How the figures are defined and sourced
6D:/special/02-otc-vitamins/regulatory/fda_otc_compliance.md22ef44a569bc22d2Supplement classification, no disease claims
7D:/special/82-alchemy-calc-two/1 light trigger.txt2dcb359de3f1b56dDepositions 328, 486, 1399
8D:/manager/book-ocr-2017-invent-depositions/entries-clean.csvad3b87e885814dbb2017 catalog anchor of the depositions
9D:/USPTO Responses/Receipts/N417.PYMT (3).pdf4982720f8492db7819/693,405 received 2026-05-30
10D:/manager/patent-build/NONPROVISIONAL-CGB-Framework.docx15caad8f09a48004Project 2, [0022], claim 15
11D:/manager/work/2 current_work_catalog.txt5b7a680d2563d031Claim 15 exact as filed
12D:/manager/export_catalog_product_20260408_165843.csv1ec6bd9793cf5541Store listing created 2026-03-09
13D:/special/crione-static/delivery-v2/payment_links_ledger.live.json96abb64653254b86Card Payment Link 2026-10-08
14D:/special-disc/02-otc-vitamins__2026-09-04.zipcacaeebfc96c2cc8Delivery file of record
15D:/manager/first-to-market/wayback_evidence.jsona0dde412013594b5Third-party web captures
16D:/special/crione-static/delivery-v2/deliver.pya4ace02b3b7d341bPrivate 7-day links; NDA text in delivery e-mail

9. Notice Line

© 2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application No. 19/693,405.

This invention blueprint: OTC Vitamins · $300M.
cri-one.com/02-otc-vitamins.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.
Go to cart
Page 1 of 1
0% read